Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments for autosomal dominant polycystic kidney disease (ADPKD), the leading genetic cause of end-stage renal failure. Renasant is advancing a pipeline of oral small molecule corrector and potentiator programs that target the underlying biology of ADPKD to restore the function of key proteins to halt disease progression.
Investors 1
Mentions in press and media 3
| Date | Title | Description |
| 14.07.2025 | Renasant Bio Raises $54.5 in Seed Funding |
BERKELEY, CA, Renasant Bio (Renasant), announced its launch and has raised $54.5 million in seed funding.
>> Click here for more funding data on Renasant Bio
>> To export Renasant Bio funding data to PDF and Excel, click here
R... |
| 10.07.2025 | Renasant Bio Raises $54.5M in Seed Funding | Renasant Bio, a Berkeley, CA-based developer of disease-modifying treatments for autosomal dominant polycystic kidney disease (ADPKD), raised $54.5M in Seed funding.
The round was led by 5AM Ventures, alongside other life sciences investors... |
| - | Renasant Bio | “Home | RenasantBio” |
Reviews 0
